ABVC BioPharma (ABVC) Competitors

ABVC BioPharma (NASDAQ:ABVC) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, community ranking, dividends, earnings, analyst recommendations, valuation and risk.

Does the MarketBeat Community favor ABVC or CTXR?

Citius Pharmaceuticals received 212 more outperform votes than ABVC BioPharma when rated by MarketBeat users.

Company	Underperform	Outperform
ABVC BioPharma	N/A	N/A
Citius Pharmaceuticals	Outperform Votes 212 62.54%	Underperform Votes 127 37.46%

Do analysts recommend ABVC or CTXR?

Citius Pharmaceuticals has a consensus price target of $54.50, indicating a potential upside of 2,927.78%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Citius Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the media favor ABVC or CTXR?

In the previous week, ABVC BioPharma and ABVC BioPharma both had 2 articles in the media. ABVC BioPharma's average media sentiment score of 0.55 beat Citius Pharmaceuticals' score of -0.75 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Which has more volatility and risk, ABVC or CTXR?

ABVC BioPharma has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in ABVC or CTXR?

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 11.9% of ABVC BioPharma shares are held by company insiders. Comparatively, 12.1% of Citius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is ABVC or CTXR more profitable?

Citius Pharmaceuticals has a net margin of 0.00% compared to ABVC BioPharma's net margin of -1,619.65%. Citius Pharmaceuticals' return on equity of -51.69% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	-1,619.65%	-104.94%	-56.81%
Citius Pharmaceuticals	N/A	-51.69%	-37.60%

Which has better earnings & valuation, ABVC or CTXR?

ABVC BioPharma has higher revenue and earnings than Citius Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$150K	60.54	-$10.52M	-$0.86	-0.81
Citius Pharmaceuticals	N/A	N/A	-$39.14M	N/A	N/A

Summary

Citius Pharmaceuticals beats ABVC BioPharma on 11 of the 14 factors compared between the two stocks.